Takeuchi S, Yamada T, Sekine H, Katoh M, Washizuka M, Fukui I, Yokokawa M
Hinyokika Kiyo. 1984 Nov;30(11):1619-25.
Eleven patients with invasive bladder cancer were treated with combination chemotherapy consisting of bleomycin (5 mg, i.m., day 1-7), vincristine (1 mg/sq.m.i.v., day 8) and methotrexate (200-300 mg/sq.m.i.v. day 8). Chemotherapy was started about 4 weeks following total cystectomy and repeated every 2 or 3 weeks at least for one year. Five of the patients were free of disease at the mean follow-up time of 35.6 months, ranging from 21 to 50 month. The 3-year survival rate was 54.5%. Bone marrow suppression (36%), nausea and vomiting (55%) were observed, but they were not serious and well tolerated. These results suggest that this regimen could be used safely as an adjuvant chemotherapy following total cystectomy for patients with invasive bladder cancer. Further evaluation will be necessary.
11例浸润性膀胱癌患者接受了联合化疗,化疗方案包括博来霉素(5毫克,肌肉注射,第1 - 7天)、长春新碱(1毫克/平方米,静脉注射,第8天)和甲氨蝶呤(200 - 300毫克/平方米,静脉注射,第8天)。化疗在全膀胱切除术后约4周开始,每2或3周重复一次,至少持续一年。5例患者在平均35.6个月(范围为21至50个月)的随访期内无疾病复发。3年生存率为54.5%。观察到有骨髓抑制(36%)、恶心和呕吐(55%),但这些症状并不严重,耐受性良好。这些结果表明,该方案可安全地用作浸润性膀胱癌患者全膀胱切除术后的辅助化疗。还需要进一步评估。